Collegium Pharmaceutical (COLL) EV to EBITDA (2015 - 2026)

Collegium Pharmaceutical has reported EV to EBITDA for 12 years, with the latest figure at 186.41 in Q2 2026.

• On a quarterly basis, EV to EBITDA rose 850.47% year-over-year to 186.41 in Q2 2026; TTM through Jun 2026 was 6.43, a 19.41% increase from a year earlier, with the FY2025 full-year figure at 5.88, up 38.5% from the prior year.
• EV to EBITDA was 186.41 for Q2 2026 at Collegium Pharmaceutical, up from 20.73 in the prior quarter.
• The five-year high for EV to EBITDA was 186.41 in Q2 2026, with the low at 58.31 in Q1 2022.
• Average EV to EBITDA over 5 years is 27.24, with a median of 19.49 recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: EV to EBITDA tumbled 289.66% in 2022, then soared 850.47% in 2026.
• Over 5 years, EV to EBITDA stood at 52.02 in 2022, then plunged by 79.11% to 10.87 in 2023, then soared by 78.19% to 19.36 in 2024, then decreased by 8.09% to 17.8 in 2025, then soared by 947.34% to 186.41 in 2026.
• The last three EV to EBITDA figures came in at 186.41 (Q2 2026), 20.73 (Q1 2026), and 17.8 (Q4 2025), per Business Quant data.